Search
CIGB 2020 Vaccine
go.drugbank.com/drugs/DB15808ExperimentalThe vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.
(1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid
go.drugbank.com/drugs/DB03455ExperimentalThis compound belongs to the indole-3-acetic acid derivatives. … These are compounds containing an acetic acid (or a derivative) linked to the C3 carbon atom of an indole. (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is known to target interleukin-2.
Lepzacitinib
go.drugbank.com/drugs/DB21646InvestigationalThe usage of the INN stem '-citinib' in the name indicates that Lepzacitinib is a Janus kinase inhibitor. … Lepzacitinib is under investigation in clinical trial NCT05432596 (Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis).
4-Hydroxytestosterone
go.drugbank.com/drugs/DB01485IllicitInvestigationalIt is specifically the 17-hydroxylated analog to formestane. … 4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom.
ARCoV
go.drugbank.com/drugs/DB15855ExperimentalSARS-CoV-2 mRNA vaccine (ARCoV) is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2[A220048]. … It is the first COVID-19 mRNA vaccine to be approved for clinical trials in China, and was co-developed by Abogen Biosciences, Walvax Biotechnolgoy Co., Ltd. and the People’s Liberation Army (PLA) Academy
Neuropeptide Y
go.drugbank.com/drugs/DB11788ApprovedInvestigationalWithdrawnNeuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.
Carlumab
go.drugbank.com/drugs/DB12718ApprovedWithdrawnCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
NNZ-2591
go.drugbank.com/drugs/DB15601InvestigationalIt was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]
Diazepinomicin
go.drugbank.com/drugs/DB12420InvestigationalIt is a proprietary first-in-class small molecule with the potential to treat multiple solid tumours like the well known chemotherapeutics, doxorubicin and mitomycin C. … Diazepinomicin has been used in trials studying the treatment of Glioblastoma Multiforme.
Synonyms: 4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo(b,e)(1,4)diazepin-11-oneHorse chestnut
go.drugbank.com/drugs/DB13195InvestigationalThe active component of this pure extract is escin, or aescin, that promotes blood circulation through the veins and reduces swelling and inflammation of the legs. … These seeds are processed to remove the toxic component, resulting in purified horse chestnut seed extract (HCSE) [A27200].